HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc. (OTCQX: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced the appointment of Michael J. Garrison to its Board of Directors, bringing the number of board members to four.
